The PARP2 Knockout Raji Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout population of the PARP2 gene in the Raji B lymphocyte host. This polyclonal format provides a heterogeneous mixture of edited cells, preserving the natural diversity of mutational outcomes and facilitating the study of PARP2 loss-of-function in a relevant B cell context without the bias of clonal selection.
Derived from a Burkitt??s lymphoma patient, Raji cells are an established human B lymphocyte line extensively utilized in immunological and cancer research. These cells constitutively produce antibodies and model adaptive immune responses, making them a valuable platform for investigating B cell biology, lymphomagenesis, and therapeutic interventions.
PARP2 functions as a DNA damage sensor, catalyzing the synthesis of poly(ADP-ribose) (PAR) chains on itself and target proteins in response to DNA single-strand breaks triggered by oxidative stress or alkylating agents. This PARylation activity recruits key base excision repair (BER) effectors such as XRCC1 and LIG3 to damage sites, facilitating repair and maintaining genomic stability. PARP2 also interacts with PARP1, histones, and PCNA, and contributes to chromatin remodeling and modulation of transcription factors including NF-??B. Its catalytic action is part of a broader DNA damage response network involving ATM and ATR kinases, linking DNA repair to cell survival and inflammatory signaling pathways.
In the Raji B lymphocyte background, PARP2 disruption offers a physiologically relevant system to dissect the role of PARP2 in DNA damage responses within the context of antibody-producing cells and lymphomagenesis. Because Raji cells retain active DNA repair and NF-??B signaling, this knockout model can elucidate how PARP2 loss influences sensitivity to PARP inhibitors and genotoxic agents, as well as impacts on cell viability and immune-related gene expression. The polyclonal nature further captures the spectrum of cellular responses, strengthening the translational relevance of mechanistic findings in B cell malignancies and inflammatory conditions.
This product is ideally suited for DNA repair mechanism studies, PARP inhibitor sensitivity screening, B cell biology research, and testing of DNA-damaging agents. Representative assays include Western blotting for PARP2 and global PARylation levels, comet assay for DNA fragmentation, cell viability assays under PARP inhibitor treatment, immunofluorescence detection of ??-H2AX foci, and RT-qPCR profiling of DNA repair genes. For further technical details or to discuss custom applications, please contact Ascent Research.
